on NFL BIOSCIENCES (EPA:ALNFL)
NFL Biosciences Reveals 2024 Results and Updates Clinical Progress
NFL Biosciences, a biopharmaceutical company based in Montpellier, presented its 2024 financial results and clinical advancements. Key progress includes the development of NFL-101, a pioneering treatment for smoking cessation. Phase 2 studies confirmed its efficacy and safety, showing promise for the planned Phase 3 trial.
The company aims to fund the first part of the Phase 3 trial, with a budget of €5 million, through partnerships or non-dilutive financing. NFL Biosciences maintains financial visibility until early Q4 2025, with ongoing discussions to support the clinical program.
Financially, NFL Biosciences reported no net revenue for 2024, an improvement in EBIT, and a net income of (2,080) k€, reflecting focused R&D spending. The company's cash reserves stand at €1.9 million, underscoring the need for strategic financing and partnerships.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NFL BIOSCIENCES news